Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

164.92
-4.8150-2.84%
Post-market: 165.150.2350+0.14%17:38 EST
Volume:1.12M
Turnover:187.39M
Market Cap:10.02B
PE:-27.23
High:172.00
Open:170.38
Low:164.78
Close:169.73
52wk High:182.99
52wk Low:95.49
Shares:60.77M
Float Shares:58.65M
Volume Ratio:1.09
T/O Rate:1.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0558
EPS(LYR):9.06
ROE:-9.06%
ROA:4.88%
PB:2.53
PE(LYR):18.21

Loading ...

FDA approves combo of Jazz’s lurbinectedin and Roche’s atezolizumab for ES-SCLC

TIPRANKS
·
Oct 03

FDA Approves Lurbinectedin in Combination With Atezolizumab or Atezolizumab and Hyaluronidase-Tqjs for Extensive-Stage Small Cell Lung Cancer- Website

THOMSON REUTERS
·
Oct 03

Jazz Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Sep 24

Morgan Stanley Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Sep 24

Jazz Pharmaceuticals announces new evidence, Phase 4 data on Xywav

TIPRANKS
·
Sep 22

Jazz Pharmaceuticals Announces Promising Phase 4 Data for Xywav® in Treating Narcolepsy and Idiopathic Hypersomnia at World Sleep and Psych Congresses

Reuters
·
Sep 22

Amneal Pharmaceuticals Inc. Receives FDA Approval for Sodium Oxybate Oral Solution, Expanding Access for Narcolepsy Patients

Reuters
·
Sep 11

Design Therapeutics Appoints Industry Veteran Justin Gover to Board of Directors, Dr. Arsani William Steps Down

Reuters
·
Sep 11

BRIEF-Modeyso™ (dordaviprone) Added to NCCN Guidelines for H3 K27M-Mutant Diffuse Glioma

Reuters
·
Sep 09

Jazz Pharmaceuticals' Modeyso™ Gains FDA Accelerated Approval for Treatment of H3 K27M-Mutant Diffuse Glioma

Reuters
·
Sep 09

Modeyso™ (Dordaviprone) Included in National Comprehensive Cancer Network® (Nccn®) Clinical Practice Guidelines in Oncology for H3 K27m-Mutant Diffuse Glioma

THOMSON REUTERS
·
Sep 09

Roche Holding AG Receives CE IVDR Approval for Expanded Use of VENTANA HER2 (4B5) Diagnostic Test in Breast and Biliary Tract Cancer

Reuters
·
Sep 05

Director Bruce C. Cozadd Reports Disposal of Common Shares of Jazz Pharmaceuticals plc

Reuters
·
Sep 05

Jazz Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 29

Jazz Pharmaceuticals Price Target Maintained With a $202.00/Share by Needham

Dow Jones
·
Aug 28

RBC Raises Price Target on Jazz Pharmaceuticals to $151 From $145, Keeps Outperform Rating

MT Newswires Live
·
Aug 28

Veeva Systems Inc : Morgan Stanley Raises Target Price to $222.00 From $210.00

THOMSON REUTERS
·
Aug 28

Five Below Inc : Morgan Stanley Raises Target Price to $160.00 From $135.00

THOMSON REUTERS
·
Aug 28

Williams-Sonoma Inc : Morgan Stanley Raises Target Price to $200.00 From $185.00

THOMSON REUTERS
·
Aug 28

Urban Outfitters Inc : Morgan Stanley Raises Target Price to $84.00 From $82.00

THOMSON REUTERS
·
Aug 28